DUBLIN, March 9, 2011 /PRNewswire/ — Trinity Biotech plc
(Nasdaq:
TRIB), a leading developer and manufacturer of diagnostic
products for the point-of-care and clinical laboratory markets,
today announced that it will present at the ROTH Capital Partners
23rd Annual OC Growth Stock Conference at the Ritz-Carlton Laguna
Beach on Monday, March 14, 2011 at 12:30 pm Pacific Time. Ronan
O’Caoimh, Chief Executive Officer, will review the company’s
business strategy and recent corporate events.
About Trinity Biotech plcTrinity Biotech develops, acquires,
manufactures and markets diagnostic systems, including both
reagents and instrumentation, for the point-of-care and clinical
laboratory segments of the diagnostic market. The products are used
to detect infectious diseases and blood coagulation disorders, and
to quantify the level of Haemoglobin A1c and other chemistry
parameters in serum, plasma and whole blood. Trinity Biotech sells
direct in the United States, Germany, France and the U.K. and
through a network of international distributors and strategic
partners in over 75 countries worldwide. For further information
please see the company’s website: http://www.trinitybiotech.com.Contact:Trinity
Biotech plcLytham Partners LLC Kevin TansleyJoe Diaz, Joe
Dorame & Robert Blum (353)-1-27698002-889-9700
E-mail:
kevin.tansley@trinitybiotech.com
‘/>”/>
